MiMedx GroupMDXG +2.10%57 FCF Margin % is 2.22% as of Mar. 2026, which is 71% below its 10-year median of 7.53. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.96 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, MiMedx Group ranks better than 88.01% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MiMedx Group's Free Cash Flow for the
three
months ended in Mar. 2026 was $1.3 Mil. MiMedx Group's Revenue for the
three
months ended in Mar. 2026 was $59.0 Mil. Therefore, MiMedx Group's FCF Margin % for the quarter that ended in Mar. 2026 was 2.22%.
The historical rank and industry rank for MiMedx Group's FCF Margin % or its related term are showing as below:
MDXG'
s FCF Margin % Range Over the Past 10 Years
Min: -13.89 Med: 7.53 Max: 18.49
Current: 17.81
During the past 13 years, the highest FCF Margin % of MiMedx Group was 18.49%. The lowest was -13.89%. And the median was 7.53%.
MDXG's FCF Margin % is ranked better than 88.01% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs MDXG: 17.81
MiMedx Group FCF Margin % Related Terms
MiMedx Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for MiMedx Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MiMedx Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where MiMedx Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a FCF Margin % of 2.22% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MiMedx Group and its competitors. This is 71% below median its historical median of 7.53. According to the industry distribution chart, MiMedx Group ranks #115 out of 959 companies in the Biotechnology industry, placing it in the top 12%.
Is MiMedx Group's FCF Margin % too high?
MiMedx Group's current FCF Margin % of 2.22% is 71% below median its 10-year median of 7.53. Based on the distribution chart, MiMedx Group ranks #115 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's FCF Margin % compare to ASMB and AGMB?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #115 out of 959 companies for FCF Margin %. This places MiMedx Group in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MiMedx Group and its competitors. MiMedx Group's current FCF Margin % is 2.22%, which is 71% below median its own 10-year median of 7.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.96, compared to a current price of $3.90 — trading 44% below its estimated fair value. The current FCF Margin % is 2.22%, which is 71% below median its 10-year median of 7.53. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MiMedx Group (MDXG), the current FCF Margin % is 2.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.90 is trading 44% below its estimated GF Value™ of $6.96.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
FCF Margin %: 2.22% (71% below median its 10-year median of 7.53)
GF Value™: $6.96 vs. price of $3.90 (44% below fair value)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
